Treasury Wine Estates to buy California's DAOU Vineyards for $900 million
By Stuart Condie
SYDNEY -- Treasury Wine Estates (AU:TWE) will buy California-based DAOU Vineyards for up to $1 billion in a move the Australia-based producer said provides it with scale to launch a future standalone Americas luxury division.
Treasury on Tuesday said it agreed to pay $900 million up front for what it called the fastest-growing luxury wine brand in U.S. trade over the 12 months through Oct. 8. It could pay up to $100 million in additional earn-outs linked to growth targets over the three years through 2027.
The ASX-listed company said that the acquisition would accelerate its focus on its so-called premiumization strategy. Treasury over recent years has been increasing its focus on higher-margin premium wines in response to changing consumer trends and a crowded lower-end market.
Treasury will fund the acquisition with a fully underwritten entitlement offer of 825 million Australian dollars ($525.9 million), a A$157 million share placement, and $311 million of debt from a new $350 million facility.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-30-23 1823ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks